Abstract
Gastrointestinal stromal tumour (GIST) is the commonest mesenchymal tumour to affect the gastrointestinal tract. Appropriate management requires accurate diagnosis and the skills of a multidisciplinary team. Surgery is the only curative treatment option and should be performed whenever feasible, by experienced personnel. For patients with advanced unresectable or metastatic disease, the receptor tyrosine kinase inhibitor imatinib offers effective therapy and can provide effective palliation for the majority of patients with this disease. The background to this recent development and a guideline for the management of GIST is proposed.
Full Text
The Full Text of this article is available as a PDF (295.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 Jan 23;279(5350):577–580. doi: 10.1126/science.279.5350.577. [DOI] [PubMed] [Google Scholar]
- Kindblom L. G., Remotti H. E., Aldenborg F., Meis-Kindblom J. M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998 May;152(5):1259–1269. [PMC free article] [PubMed] [Google Scholar]
- Nielsen Torsten O., West Rob B., Linn Sabine C., Alter Orly, Knowling Margaret A., O'Connell John X., Zhu Shirley, Fero Mike, Sherlock Gavin, Pollack Jonathan R. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002 Apr 13;359(9314):1301–1307. doi: 10.1016/S0140-6736(02)08270-3. [DOI] [PubMed] [Google Scholar]
- Plaat B. E., Hollema H., Molenaar W. M., Torn Broers G. H., Pijpe J., Mastik M. F., Hoekstra H. J., van den Berg E., Scheper R. J., van der Graaf W. T. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000 Sep 15;18(18):3211–3220. doi: 10.1200/JCO.2000.18.18.3211. [DOI] [PubMed] [Google Scholar]
- Sircar K., Hewlett B. R., Huizinga J. D., Chorneyko K., Berezin I., Riddell R. H. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999 Apr;23(4):377–389. doi: 10.1097/00000478-199904000-00002. [DOI] [PubMed] [Google Scholar]
- Van Glabbeke M., van Oosterom A. T., Oosterhuis J. W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999 Jan;17(1):150–157. doi: 10.1200/JCO.1999.17.1.150. [DOI] [PubMed] [Google Scholar]
- van Oosterom A. T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001 Oct 27;358(9291):1421–1423. doi: 10.1016/s0140-6736(01)06535-7. [DOI] [PubMed] [Google Scholar]